308 related articles for article (PubMed ID: 29616044)
21. Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study.
Chiereghin A; Piccirilli G; Belotti T; Prete A; Bertuzzi C; Gibertoni D; Gabrielli L; Turello G; Borgatti EC; Barbato F; Sessa M; Arpinati M; Bonifazi F; Lazzarotto T
Med Microbiol Immunol; 2019 Dec; 208(6):825-834. PubMed ID: 31289930
[TBL] [Abstract][Full Text] [Related]
22. Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.
Sutrave G; Blyth E; Gottlieb DJ
Cytotherapy; 2017 Nov; 19(11):1284-1301. PubMed ID: 28927824
[TBL] [Abstract][Full Text] [Related]
23. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
McLaughlin LP; Rouce R; Gottschalk S; Torrano V; Carrum G; Wu MF; Hoq F; Grilley B; Marcogliese AM; Hanley PJ; Gee AP; Brenner MK; Rooney CM; Heslop HE; Bollard CM
Blood; 2018 Nov; 132(22):2351-2361. PubMed ID: 30262660
[TBL] [Abstract][Full Text] [Related]
24. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.
Bollard CM; Savoldo B; Rooney CM; Heslop HE
Acta Haematol; 2003; 110(2-3):139-48. PubMed ID: 14583674
[TBL] [Abstract][Full Text] [Related]
25. Adoptive Cell Transfer of Allogeneic Epstein-Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report.
Hansen BT; Bacher P; Eiz-Vesper B; Heckl SM; Klapper W; Koch K; Maecker-Kolhoff B; Baldus CD; Fransecky L
Front Immunol; 2021; 12():727814. PubMed ID: 34925312
[TBL] [Abstract][Full Text] [Related]
26. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.
Heslop HE; Savoldo B; Rooney CM
Best Pract Res Clin Haematol; 2004 Sep; 17(3):401-13. PubMed ID: 15498712
[TBL] [Abstract][Full Text] [Related]
27. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
28. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
29. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
30. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
Tse E; Kwong YL
Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for transplantation-associated viral infections.
Roddie C; Peggs KS
J Clin Invest; 2017 Jun; 127(7):2513-2522. PubMed ID: 28628043
[TBL] [Abstract][Full Text] [Related]
32. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
33. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
Worth AJ; Houldcroft CJ; Booth C
Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
Finberg RW
Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
[TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
[No Abstract] [Full Text] [Related]
36. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
Ricciardelli I; Brewin J; Lugthart G; Albon SJ; Pule M; Amrolia PJ
Am J Transplant; 2013 Dec; 13(12):3244-52. PubMed ID: 24266973
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for Epstein-Barr virus-associated tumors.
Comito MA; Sun Q; Lucas KG
Leuk Lymphoma; 2004 Oct; 45(10):1981-7. PubMed ID: 15370241
[TBL] [Abstract][Full Text] [Related]
38. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
39. The immunology of Epstein-Barr virus-induced disease.
Taylor GS; Long HM; Brooks JM; Rickinson AB; Hislop AD
Annu Rev Immunol; 2015; 33():787-821. PubMed ID: 25706097
[TBL] [Abstract][Full Text] [Related]
40. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
